Current disease status-Recurrent leukemia - Page 7 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Stepping-up dosing approach for ofatumumab is safe and reduces administration time

Stepping-up dosing approach for ofatumumab is safe and reduces administration time

Posted by on Nov 7, 2017 in Leukemia | 0 comments

In a nutshell This study tested the safety of ofatumumab (Arzerra) when administered using a stepping-up dosing approach. The approach was found to be safe and well tolerated. Some background Chemotherapy and immunotherapy are usually the first-line treatment of CLL. In cases of disease relapse, alternative treatment options are usually explored....

Read More

Long-term outcomes of allogeneic stem cell transplantations in young high-risk CLL patients

Posted by on Oct 5, 2017 in Leukemia | 0 comments

In a nutshell This study examined predictors of outcomes with stem cell transplantation from a donor (allo-SCT) for chronic lymphocytic leukemia (CLL). Researchers reported good long-term outcomes for young high-risk CLL patients treated with allo-SCT. Patients with matched sibling donors showed better outcomes compared to those with matched unrelated...

Read More

Side effects of ibrutinib and idelalisib treatment

Side effects of ibrutinib and idelalisib treatment

Posted by on Sep 22, 2017 in Leukemia | 0 comments

In a nutshell In this review, the authors look at the most common adverse events related to ibrutinib and idelalisib, B-cell inhibitors. The study concluded that both ibrutinib and idelalisib are effective at treating B-cell cancers, and the side effects are within a normal range compared to other similar treatments. Some background Ibrutinib and...

Read More

Pembrolizumab in patients with chronic lymphocytic leukemia with Richter’s transformation

Pembrolizumab in patients with chronic lymphocytic leukemia with Richter’s transformation

Posted by on Sep 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of pembrolizumab in the treatment of chronic lymphocytic leukemia that has undergone Richter’s transformation. This study concluded that patients with Richter’s transformation responded to pembrolizumab.  Some background Chronic lymphocytic leukemia is a cancer where...

Read More

Treatment outcomes in 477 patients with blast-phase CML

Treatment outcomes in 477 patients with blast-phase CML

Posted by on Sep 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined treatment outcomes in patients with blast-phase chronic myeloid leukemia (CML). Authors reported that intensive treatment early followed by stem cell transplantation remains as the most effective approach. Certain patient characteristics and treatment history are significant predictors of outcomes.  Some...

Read More

Inotuzmab ozogamicin as a treatment option for patients with acute lymphoblastic leukaemia.

Posted by on Sep 14, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if inotuzumab ozogamicin (Besponsa) is a more effective treatment than the standard therapy for relapsed acute lymphoblastic leukemia. This study concluded that inotuzumab ozogamicin is a more effective treatment than standard therapy for relapsed acute lymphoblastic leukemia.   Some background...

Read More

Searching for patients to test the effectiveness of venetoclax with ibrutinib in treating chronic lymphocytic leukemis

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...

Read More

Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment

Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment

Posted by on Sep 3, 2017 in Leukemia | 0 comments

In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...

Read More

Could interferon-alpha benefit acute leukemia patients who have minimal residual disease after stem cell transplants?

Could interferon-alpha benefit acute leukemia patients who have minimal residual disease after stem cell transplants?

Posted by on Aug 19, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of interferon-alpha (IFN-α) in acute leukemia patients with minimal residual disease after stem cell transplantation. This study concluded that IFN-α is an effective treatment for acute leukemia patients with minimal residual disease after stem cell...

Read More

Is there a benefit of reduced-intensity conditioning plus imatinib compared to imatinib alone?

Is there a benefit of reduced-intensity conditioning plus imatinib compared to imatinib alone?

Posted by on Aug 14, 2017 in Leukemia | 0 comments

In a nutshell This study examined two types of treatment regimes involving imatinib (Gleevac) for chronic myeloid leukemia (CML). Patients receiving reduced-intensity chemotherapy and a stem cell transplant before imatinib had similar outcomes to patients treated with imatinib alone. Some background Targeted therapy has become the standard...

Read More

Remaining leukemia cells have a negative impact on stem cell transplantation in AML

Remaining leukemia cells have a negative impact on stem cell transplantation in AML

Posted by on Jul 30, 2017 in Leukemia | 0 comments

In a nutshell This study looked at the effect of remaining leukemia cells (present in bone marrow during remission) on stem cell transplant outcomes in acute myeloid leukemia patients. The study concluded that the presence of leukemia cells prior to stem cell transplantation has a negative effect on patient outcomes.  Some background Adult...

Read More